SCHEMBL23306334

SCHEMBL23306334

Cn1ccc2cc(Cl)nc(C(=O)O)c21

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
XDH P47989 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
HSD17B10 Q99714 1/20 0.38
ALDH1A1 P00352 3/20 0.34
MAPK1 P28482 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
PKM P14618 1/20 0.34
KMO O15229 1/20 0.33
MAOB P27338 1/20 0.32
PIN1 Q13526 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
PTGDR2 Q9Y5Y4 1/20 0.32
EGLN1 Q9GZT9 1/20 0.32
MAPT P10636 1/20 0.32
KDR P35968 1/20 0.32
GRM5 P41594 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15525131 0.87 PTGS2 (0.35) XDHMEN1KMT2ACYP2C9CYP2C19
SCHEMBL15525083 0.83 KDM4E (0.40) KMT2ACYP2C9CYP2C19HSD17B10ALDH1A1
SCHEMBL15525111 0.74 KDM4E (0.32) KMT2AALDH1A1MAPK1SMN1; SMN2TDP1
SCHEMBL16517811 0.73 L3MBTL1 (0.44) ALDH1A1EGLN1
SCHEMBL7920908 0.72 TTR (0.44) XDHMEN1KMT2ACYP2C9MAOB
SCHEMBL16533801 0.67 KDM4E (0.40) HSD17B10ALDH1A1SMN1; SMN2PKMMAPT
SCHEMBL30829604 0.67 MYC (0.40) XDHMEN1KMT2AHSD17B10ALDH1A1
SCHEMBL31347270 0.67 KDM4E (0.40) MEN1KMT2ACYP2C9CYP2C19HSD17B10
SCHEMBL26105200 0.67 KDM4E (0.40) MEN1KMT2ACYP2C9CYP2C19HSD17B10
SCHEMBL16046019 0.66 PIK3CB (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021087087-A1 N-CYCLOHEXYL-5-(THIAZOL-5-YL)-1H-INDOLE-7-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS CD38 INHIBITORS FOR INCREASING NAD+ AND FOR THE TREATMENT OF E.G. MUSCULAR DISORDERS MITOBRIDGE INC. (US) 2021-05-06 WO disclosed